外泌体miRNA作为乳腺癌生物标志物的临床应用

国际肿瘤学杂志››2019,Vol. 46››Issue (7): 423-426.doi:10.3760/cma.j.issn.1673-422X.2019.07.007

外泌体miRNA作为乳腺癌生物标志物的临床应用

曹黎霞，史振东，刘晶晶，张瑾

天津医科大学肿瘤医院乳腺三科国家肿瘤临床医学研究中心天津市“肿瘤防治”重点实验室天津市恶性肿瘤临床医学研究中心300060

出版日期:2019-07-08发布日期:2019-07-16
通讯作者:张瑾 E-mail:zhangjin@tjmuch.com
基金资助:

国家自然科学基金（81502306、81672623）

Clinical application of exosomal miRNA as biomarker in breast cancer

Cao Lixia, Shi Zhendong, Liu Jingjing, Zhang Jin

Third Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Clinical Research Center for Cancer of Tianjin, Tianjin 300060, China

Online:2019-07-08Published:2019-07-16
Contact:Zhang Jin E-mail:zhangjin@tjmuch.com
Supported by:

National Natural Science Foundation of China (81502306, 81672623)

摘要/Abstract

摘要：微小RNA（miRNA）具有肿瘤特异性的表达谱，且在肿瘤发生和进展中发挥重要作用，其通过外泌体的包裹免受体液中核糖核酸酶的侵害，在乳腺癌细胞之间水平转移遗传信息。近年来针对外泌体miRNA的研究发现，其与乳腺癌的发生、诊治及预后关系密切。深入探讨这一领域的研究，可为外泌体miRNA作为乳腺癌生物标志物的临床应用提供理论依据。

曹黎霞，史振东，刘晶晶，张瑾. 外泌体miRNA作为乳腺癌生物标志物的临床应用[J]. 国际肿瘤学杂志, 2019, 46(7): 423-426.

Cao Lixia, Shi Zhendong, Liu Jingjing, Zhang Jin. Clinical application of exosomal miRNA as biomarker in breast cancer[J]. Journal of International Oncology, 2019, 46(7): 423-426.

［1］ Harbeck N, Gnant M. Breast cancer［J］. Lancet, 2017, 389(10074): 11341150. DOI: 10.1016/S01406736(16)318918. ［2］ Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparibcarboplatin treatment in breast cancer［J］. N Engl J Med, 2016, 375(1): 2324. DOI: 10.1056/NEJMoa1513749. ［3］ Joyce DP, Kerin MJ, Dwyer RM. Exosomeencapsulated microRNAs as circulating biomarkers for breast cancer［J］. Int J Cancer, 2016, 139(7): 14431448. DOI: 10.1002/ijc.30179. ［4］ Sun Y, Liu J. Potential of cancer cellderived exosomes in clinical application: a review of recent research advances［J］. Clin Ther, 2014, 36(6): 863872. DOI: 10.1016/j.clinthera.2014.04.018. ［5］ Lee JH, Kim JA, Jeong S, et al. Simultaneous and multiplexed detection of exosome microRNAs using molecular beacons［J］. Biosens Bioelecton, 2016, 86: 202210. DOI: 10.1016/j.bios.2016.06.058. ［6］ Hellwinkel JE, Redzic JS. Gliomaderived extracellular vesicles selectively suppress immune responses［J］. Neuro Oncol, 2016, 18(4): 497506. DOI: 10.1093/neuonc/nov170. ［7］ Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: celltocell mediators of metastasis［J］. Cancer Cell, 2016, 30(6): 836848. DOI: 10.1016/j.ccell.j.ccell.2016.10.009. ［8］ Kalluri R. The biology and function of exosomes in cancer［J］. J Clin Invest, 2016, 126(4): 12081215. DOI: 10.1172/JCI81135. ［9］ Frassanito MA, De Veirman K, Desantis V. Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients［J］. Leukemia, 2016, 30(3): 640648. DOI: 10.1038/leu.2015.289. ［10］ Jia Y, Chen Y, Wang Q, et al. Exosome: emerging biomarker in breast cancer［J］. Oncotarget, 2017, 8(25): 4171741733. DOI: 10.18632/oncotarget.16684. ［11］ Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver antimiR214 to reverse chemoresistance to cisplatin in gastric cancer［J］. Mol Ther, 2018, 26(3): 774783. DOI: 10.1016/j.ymthe. ［12］ Wang T, Fang L, Zhao F, et al. Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus［J］. J Virol, 2018, 92(4). pii: e0173417. DOI: 10.1128/JVI.0173417. ［13］ Moore C, Kosgodage U, Lange S, et al. The emerging role of exosome and microvesicle (EMV) based cancer therapeutics and immunotherapy［J］. Int J Cancer, 2017, 141(3): 428436. DOI: 10.1002/ijc.30672. ［14］ Gorski SA, Vogel J, Doudna JA. RNAbased recognition and targeting: sowing the seeds of specificity［J］. Nat Rev Mol Cell Biol, 2017, 18(4): 215228. DOI: 10.1038/nrm.2016.174. ［15］ Ohno S, Kuroda M. Exosomemediated targeted delivery of miRNAs［J］. Methods Mol Biol, 2016, 1448: 261270. DOI: 10.1007/9781493937530_19. ［16］ Hannafon BN. Plasma exosome microRNAs are indicative of breast cancer［J］. Breast Cancer Res, 2016, 18(1): 90. DOI: 10.1186/s130580160753x. ［17］ Naughton E. Exosomeencapsulated microRNA451a as a circulating biomarker for breast cancer［J］. Ir J Med Sci, 2017, 186 (Suppl 1): S1S39. DOI: 10.1007/s1184501615325. ［18］ Stevic I, Müller V, Weber K, et al. Specific microRNA signatures in exosomes of triplenegative and HER2positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial［J］. BMC Med, 2018, 16(1): 179. DOI: 10.1186/s129160181163y. ［19］瞿望. 采用AT方案新辅助化疗的Luminal A型乳腺癌患者血浆外泌体microRNA特征研究［D］. 北京: 北京协和医学院中国医学科学院, 2017. ［20］ Zhao L, Liu W, Xiao J, et al. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance［J］. Cancer Lett, 2015, 356(2 Pt B): 339346. DOI: 10.1016/j.canlet.2014.10.027. ［21］ Eichelser C, Stuckrath I, Muller V, et al. Increased serum levels of circulating exosomal microRNA373 in receptornegative breast cancer patients［J］. Oncotarget, 2014, 5(20): 96509663. DOI: 10.18632/oncotarget.2520. ［22］ Yoshikawa M. Exosomeencapsulated microRNA2233p as a minimally invasive biomarker for the early detection of invasive breast cancer［J］. Oncol Lett, 2018, 15(6): 95849592. DOI: 10.3892/ol.2018.8457. ［23］ O′Brien K, Lowry MC. miR134 in extracellular vesicles reduces triplenegative breast cancer aggression and increases drug sensitivity［J］. Oncotarget, 2015, 6(32): 3277432789. DOI: 10.18632/oncotarget.5192. ［24］ Hu W, Tan C, He Y, et al. Functional miRNAs in breast cancer drug resistance［J］. Onco Targets Ther, 2018, 11: 15291541. DOI: 10.2147/OTT.S152462. ［25］ Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents［J］. Clin Breast Cancer, 2010, 10(1): 6473. DOI: 10.3816/CBC.2010.n.009. ［26］ Zhou W, Fong MY, Min Y, et al. Cancersecreted miR105 destroys vascular endothelial barriers to promote metastasis［J］. Cancer Cell, 2014, 25(4): 501515. DOI: 10.1016/j.ccr.2014.03.007. ［27］ Singh R, Pochampally R, Watabe K, et al. Exosomemediated transfer of miR10b promotes cell invasion in breast cancer［J］. Mol Cancer, 2014, 13: 256. DOI: 10.1186/1476459813256. ［28］ Sueta A, Yamamoto Y, Tomiguchi M, et al. Differential expression of exosomal miRNAs between breast cancer patients with recurrence and norecurrence［J］. Oncotarget, 2017, 8(41): 6993469944. DOI: 10.18632/oncotarget.19482.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[5]	刘博翰, 黄俊星.液体活检技术在食管鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 105-108.
[6]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	张渊, 白芷玉, 李琪, 冯勤梅.外泌体在恶性肿瘤中的研究现状[J]. 国际肿瘤学杂志, 2023, 50(8): 484-488.
[12]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[13]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.